[Survival of patients with End Stage Kidney Disease].
Jean-Philippe Jais, Thierry Lobbedez, Cécile Couchoud
https://pubmed.ncbi.nlm.nih.gov/37638506/Actively Recruiting
Led by Central Hospital, Nancy, France · Updated on 2026-02-13
2293
Participants Needed
3
Research Sites
13 weeks
Total Duration
This research aims to evaluate whether regular monitoring and feedback of symptoms can improve the quality of life for patients undergoing dialysis for end-stage renal disease ESRD. The study focuses on addressing the often overlooked symptoms that affect the physical and mental health quality of life in dialysis patients. It also assesses the feasibility and cost-effectiveness of electronically capturing patient-reported outcomes within a national dialysis registry. Participants are randomly assigned to either an experimental group or a control group. The experimental group completes symptom questionnaires every three months via a digital tablet during dialysis sessions, with severe symptoms automatically reported to healthcare teams for management. The control group receives usual care without systematic symptom monitoring. Both groups complete quality of life assessments every six months over 18 months. Half of the dialysis units have a clinical research nurse supporting data collection for 12 months, followed by local teams managing data collection for the remaining six months. During the study, patients provide symptom and quality of life data through digital questionnaires completed at regular intervals during dialysis. Researchers analyze these patient-reported outcomes, clinical data from the national registry, and healthcare usage from administrative databases. Interviews with patients and healthcare professionals explore the implementation process and perceptions of the intervention. The primary outcome is the physical health score from a validated kidney disease quality of life questionnaire after 12 months. The total participation and observation period lasts 18 months, with ongoing safety and data monitoring.
CONDITIONS
Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients.
N
Nadine JUGE
A
Amandine OSTERMANN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Central Hospital, Nancy, France
Lead Sponsor
Agence de La Biomédecine
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or during dialysis session)
Duration - 18 months
Participants complete symptom and health-related quality of life questionnaires during their dialysis sessions. In the experimental group, symptoms are systematically monitored quarterly using the IPOS-Renal questionnaire, with results reported to dialysis staff to assist in symptom management. Health-related quality of life questionnaires are completed every 6 months by all participants.
Quarterly symptom monitoring and questionnaire completion for experimental group; Biannual questionnaire completion for control group
Duration - Conducted around 3 months after study start
Selected participants and healthcare professionals take part in semi-structured interviews to provide insights on the implementation and impact of the symptom monitoring system.
1 to 2 remote or in-person interviews
Duration - Up to 18 months
Data collection continues under the guidance of local healthcare teams, focusing on patient outcomes and changes in care practices up to 18 months after enrollment.
Ongoing data collection during routine dialysis sessions
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jean-Philippe Jais, Thierry Lobbedez, Cécile Couchoud
https://pubmed.ncbi.nlm.nih.gov/37638506/Kamyar Kalantar-Zadeh, Mark B Lockwood, Connie M Rhee...
https://pubmed.ncbi.nlm.nih.gov/34980890/Lavern Greenham, Paul N Bennett, Kathryn Dansie...
https://pubmed.ncbi.nlm.nih.gov/35590395/Sara N Davison, Adeera Levin, Alvin H Moss...
https://pubmed.ncbi.nlm.nih.gov/25923985/Ethan Basch, Allison M Deal, Mark G Kris...
https://pubmed.ncbi.nlm.nih.gov/26644527/Mark B Lockwood, James P Lash, Heather Pauls...
https://pubmed.ncbi.nlm.nih.gov/31714343/Divya Raghavan, Jean L Holley
https://pubmed.ncbi.nlm.nih.gov/26709063/Allison Tong, Shingisai Chando, Sally Crowe...
https://pubmed.ncbi.nlm.nih.gov/25582284/Andrea K Viecelli, Emily Duncanson, Paul N Bennett...
https://pubmed.ncbi.nlm.nih.gov/35085687/Khaled Abdel-Kader, Mark L Unruh, Steven D Weisbord
https://pubmed.ncbi.nlm.nih.gov/19423570/Central Hospital, Nancy, France
Lead Sponsor
Agence de La Biomédecine
Collaborating Sponsor